Recruitment of immune cells across atrial endocardium in human atrial fibrillation

Circulation Journal

Volumn 74, Issue 2, 2010, Pages 262-270

  Yamashita, Takeshi ^a   Sekiguchi, Akiko ^a   Iwasaki, Yu Ki ^a   Date, Taro ^a   Sagara, Koichi ^a   Tanabe, Hiroaki ^a   Suma, Hisayoshi ^a   Sawada, Hitoshi ^a   Aizawa, Tadanori ^a  

^a THE CARDIOVASCULAR INSTITUTE   (Japan)

Author keywords

Atrial fibrillation; Endocardium; Inflammation

Indexed keywords

CD45 ANTIGEN; CD68 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; SCAVENGER RECEPTOR A; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CD3+ T LYMPHOCYTE; CELL ADHESION; CELL MATURATION; CELL MIGRATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOKINE PRODUCTION; ENDOCARDIUM; FEMALE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART SURGERY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; PROTEIN EXPRESSION; SINUS RHYTHM;

ADAPTIVE IMMUNITY; ADULT; AGED; ANTIGENS, CD; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; CELL ADHESION; CELL ADHESION MOLECULES; CELL MOVEMENT; CYTOKINES; ENDOCARDIUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNITY, INNATE; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; MACROPHAGES; MALE; MIDDLE AGED; SCAVENGER RECEPTORS, CLASS A; T-LYMPHOCYTES;

EID: 75749142308     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0644     Document Type: Article

References (39)

1. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: 30-year follow-up in the Framingham Study. JAMA 1985; 254: 3449-3453.
2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001; 285: 2370-2375.
3. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-952.
4. Suzuki S, Yamashita T, Ohtsuka T, Sagara K, Uejima T, Oikawa Y, et al. Prevalence and prognosis of patients with atrial fibrillation in Japan: A prospective cohort of Shinken Database 2004. Circ J 2008; 72: 914-920.
5. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
6. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840.
7. Ogawa S, Yamashita T, Yamazaki T, Aizawa Y, Atarashi H, Inoue H, et al; J-RHYTHM Investigators. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J 2009; 73: 242-248.
8. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
9. Sjoholm A, Nystrom T. Endothelial inflammation in insulin resistance. Lancet 2005; 365: 610-612.
10. Nadar S, Blann AD, Lip GY. Endothelial dysfunction: Methods of assessment and application to hypertension. Curr Pharm Des 2004; 10: 3591-3605.
11. Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-291.
12. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006; 27: 136-149.
13. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26: 2083-2092.
14. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, et al. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891.
15. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108: 3006-3010.
16. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 2005; 95: 764-767.
17. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004; 25: 1100-1107.
18. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92: 1379-1383.
19. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92: 1343-1345.
20. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 2005; 45: 1832-1839.
21. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719.
22. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: A systematic review of the published data. J Am Coll Cardiol 2007; 50: 2021-2028.
23. Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002; 54: 361-379.
24. Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004; 90: 400-405.
25. Brundel BJ, Ausma J, van Gelder IC, Van der Want JJ, van Gilst WH, Crijns HJ, et al. Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation. Cardiovasc Res 2002; 54: 380-389.
26. de Winther MP, van Dijk KW, Havekes LM, Hofker MH. Macrophage scavenger receptor class A: A multifunctional receptor in atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 290-297.
27. Walpola PL, Gotlieb AI, Cybulsky MI, Langille BL. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress. Arterioscler Thromb Vasc Biol 1995; 15: 2-10.
28. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the apoE-deficient mouse. Arterioscler Thromb Vasc Biol 1998; 18: 842-851.
29. Terkeltaub R, Boisvert WA, Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol 1998; 9: 397-405.
30. Ylä-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991; 88: 5252-5256.
31. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-1184.
32. Nakamura Y, Nakamura K, Fukushima-Kusano K, Ohta K, Matsubara H, Hamuro T, et al. Tissue factor expression in atrial endothelium associated with nonvalvular atrial fibrillation: Possible involvement in intracardiac thrombogenesis. Thromb Res 2003; 111: 137-142.
33. Chen MC, Chang JP, Liu WH, Yang CH, Chen YL, Tsai TH, et al. Increased inflammatory cell infiltration in the atrial myocardium of patients with atrial fibrillation. Am J Cardiol 2008; 102: 861-865.
34. Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: Potential mechanisms for atrial thrombosis and stroke. Circulation 2002; 106: 2854-2858.
35. Yamashita T, Sekiguchi A, Iwasaki YK, Sagara K, Hatano S, Iinuma H, et al. Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria. Circulation 2003; 108: 2450-2452.
36. Goette A, Bukowska A, Lendeckel U, Erxleben M, Hammwöhner M, Strugala D, et al. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation 2008; 117: 732-742.
37. Dudley SC Jr, Hoch NE, McCann LA, Honeycutt C, Diamandopoulos L, Fukai T, et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: Role of the NADPH and xanthine oxidases. Circulation 2005; 111: 1266-1273.
38. Ramos-Mondragón R, Galindo CA, Avila G. Role of TGF-beta on cardiac structural and electrical remodeling. Vasc Health Risk Manag 2008; 4: 1289-1300.
39. Kapur NK, Deming CB, Kapur S, Bian C, Champion HC, Donahue JK, et al. Hemodynamic modulation of endocardial thromboresistance. Circulation 2007; 115: 67-75.